29 results about "Malignant disease" patented technology

This disclosure provides: (i) a method of using an anticeramide antibody or an antigen-binding fragment thereof to improve hematopoietic stem cell transplantation for the treatment of various non-malignant and malignant diseases; and (ii) a composition for such treatment.

The present application relates to the field of artificial intelligence and stomatology technology, and discloses a dynamic risk stratification monitoring system for potential malignant diseases in the oral cavity, which comprises a multi-modal data acquisition module, an intelligent risk assessment module, a risk grade division module and a dynamic monitoring module. The present application collects multi-modal data of the patient, including the patient's clinical behavior data, pathological data and basic identity information, carries out multi-dimensional analysis on the collected data to obtain behavior risk factors, pathological risk factors and basic risk factors, weights and sums the three factors to obtain a comprehensive risk coefficient, divides the current risk level of the patient based on the comprehensive risk coefficient, including low risk, medium risk and high risk, and draws a dynamic risk change curve of the patient based on the comprehensive risk coefficient, and determines whether to issue a warning according to the slope of the curve to attract the attention of medical staff to the current patient.

A device and a method, which is individual to a patient, treat malignant diseases by using selectively acting tumor-destructive mechanical pulses (TMI). The tumor-destructive pulse shapes and frequency are determined using physical cell properties, which are individual to each patient. The device is controlled in such that lethal pulse fields are applied in the tumor area.

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. A compound represented by formula (11) has an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and / or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.

The present invention relates to binding molecules comprising a T-cell receptor (TCR) variable domain capable of binding to a PIWIL1 peptide-HLA complex. The present invention also relates to the use of such molecules for the treatment of malignant diseases.

The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.

The invention discloses an oral potential malignant disease canceration time prediction system, electronic equipment and a medium, and the system comprises a data acquisition module, a data division module, a model construction module, a model training module and a time prediction module. And the risk prediction module is used for predicting the cancerization risk of the patient by using the artificial intelligence model with the best prediction accuracy, and determining the risk values of cancerization in the first time period and the second time period, or determining the time period with the higher cancerization possibility. According to the technical scheme, the canceration risk prediction probability values of the patient in multiple time periods are innovatively output by adopting the artificial intelligence model in combination with an oversampling technology and ending weight adjustment, a more comprehensive and specific prediction result can be provided for the patient, and personalized follow-up visit and formulation of a treatment scheme are facilitated.

The invention discloses a human breast benign and malignant disease body surface scanning detection method and device and a medium, and belongs to the technical field of biomedical instruments. The method comprises the following steps: acquiring depth data and an RGB image of a mammary gland area; planning a scanning path based on the depth data; controlling a mechanical arm to drive an optical fiber Raman probe to scan along the path; acquiring spectral data and preprocessing the spectral data; and synchronously marking the recognition result on the RGB image and displaying the RGB image. A mechanical scanning device is matched with an optical fiber Raman light probe, three-dimensional modeling of a mammary gland area is obtained through the assistance of an active infrared stereoscopic vision technology, a scanning path is automatically planned through an image edge detection algorithm, all-directional, full-automatic and high-sampling-density self-adaptive scanning is carried out on the human mammary gland, and the human mammary gland scanning precision is improved. And the benign and malignant substances of the breast tissue are judged by combining high-precision abnormal Raman spectrum detection and a mode recognition algorithm.

The present invention provides compounds of formula (I) or an enantiomer thereof, particularly the R-enantiomer, a diastereomer thereof, its hydrates, its solvates, its crystal forms, its tautomers or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, X and A are as defined herein. Said compounds of formula (I) are inhibitors of insulin-like growth factor 2 mRNA binding proteins (IGF2BP). Provided are novel inhibitors of IGF2BPs and processes for manufacturing the same. The invention further relates to a compound of formula (I) or a pharmaceutical composition for use in the treatment of any malignant disorder, including primary disease, metastases or recurrent neoplasia, which exhibits expression of IGF2BP1 in a manner amenable to the therapeutic intervention.

We disclose the generation and training of Generative Adversarial Networks (GAN) to synthesize clinical images with skin conditions. Synthetic images for a pre-specified skin condition are generated, while being able to vary its size, location and the underlying skin color. We demonstrate that the generated images are of high fidelity using objective GAN evaluation metrics. The synthetic images are not only visually similar to real images, but also embody the respective skin conditions. Additionally, synthetic skin images can be used as a data augmentation technique for training a skin condition classifier, and improve the ability of the classifier to detect rare but malignant conditions.

A method for diagnosing a malignant proliferative disease or disorder in a subject, and / or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

This application relates to the field of biotechnology, specifically disclosing a methylation molecular marker and its detection kit for early warning of oral mucosal cancer. The methylation molecular markers are the ZNF582 and SHOX2 genes. This application provides important molecular information for oral cancer screening by detecting the methylation levels of the ZNF582 and SHOX2 genes. The molecular markers of this application have high accuracy, sensitivity, and specificity, providing an important reference for early warning of oral mucosal cancer. Furthermore, the detection method is simple, rapid, low-cost, and convenient to sample, which can help achieve non-invasive early warning of potential oral malignant diseases, showing promising application prospects.

The present invention relates to binding molecules comprising a T cell receptor (TCR) variable domain capable of binding to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) complexed with HLA-A24. The present invention also relates to the use of such molecules for the treatment of malignant diseases.

Various methods of treating a disease or condition, such as cancer, autoimmune disease, or any disease involving cellular proliferation are presented herein comprising administering to the subject an effective amount of an HPDL inhibitor compound or pharmaceutical composition as described herein.

Described is a vaccine for use in actively immunising a subject against an infectious disease or a malignant disease, said vaccine comprising: (a) an antibody against an antigen correlated with said infectious disease or malignant disease; or (b) an Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen correlated with said infectious disease or malignant disease, wherein said Fc part is capable of binding a receptor present on or in an antigen presenting cell (APC) selected from the group consisting of Type I: activatory FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa, FcγRIIIb, and inhibitory FcγRIIb; and Type II: neonatal FcR (FcRn) and cytosolic TRIM21. Moreover, described is a vaccine for use in actively immunising a subject against an HSV-associated disease; and (a) wherein said antibody is an anti-HSV antibody and said subject suffers from an acute HSV-associated disease, preferably an acute HSV infection; or (b) wherein in said Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen, the antigen correlates with an HSV-associated disease.

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and / or a syndrome due to glucocorticoid excess such as hypercortisolemia.

The present invention relates to a method for preparing a porphyrin compound of formula (I) or its metallo-derivatives, salts, and solvates, particularly its tin(IV) phosphate derivative [wherein R1, R2, R3, R4, R5, and R6 are each independently H, methyl, ethyl, halogen, methoxy, ethoxy, NR'R'', C 1-2 Haloalkyl, C 1-2 The present invention relates to porphyrins selected from alkanamines and C(O)CH3. The present invention also relates to pharmaceuticals, in particular pharmaceuticals for use in the treatment of proliferative and / or malignant diseases (such as cancer) and for use in treating or inhibiting metastasis, as well as pharmaceutical compositions containing such porphyrins. [Formula 1] JPEG2026509438000119.jpg72170

The present application relates to the present application relates to the curcumin loaded manganese doped bioactive glass microneedle patch and preparation method and application, relates to the field of biomedical materials technology. The curcumin loaded manganese doped bioactive glass microneedle patch is composed of manganese doped bioactive glass nanoparticles containing curcumin and microneedle matrix material, which can effectively penetrate the oral mucosal barrier, deliver Mn 2+ And curcumin to the lesion site, regulate the immune microenvironment by Mn 2+ Inhibition of abnormal proliferation, while curcumin plays an anti-inflammatory and antioxidant stress role, synergistically inhibits the occurrence and carcinogenesis of potential malignant diseases in the oral cavity. The preparation process of the present application is simple, the product has good biocompatibility, and the active ingredients can be slowly released, which provides a new strategy for the treatment of potential malignant diseases in the oral cavity.

There is described herein methods for assessing survival risk of a human subject with haematological cancer or an age-related non-malignant disease. The method comprises analysis of at least 1000 of the 31744 differentially methylated regions (DMRs) set forth in Table 1 by determining an epigenetically stable loci (ESL) profile based on the methylation status of the at least 1000 DMRs; and categorizing the subject as having either low survival risk or high survival risk, each being associated with high DNA methylation instability (DMI) or low DMI respectively, wherein the subject has high DMI if the ESL profile has methylated DMRs exceeding a predetermined threshold and the subject has low DMI if the ESL profile has methylated DMRs below the predetermined threshold.

This application provides a system, method, media, program product, and terminal for vascular biomarker analysis and disease diagnosis based on ultrasound-guided microscopy. This application utilizes a unified and optimized ULM (Ultra-Large-Scale Microscopy) workflow to reconstruct complex vascular networks with high precision and resolution. It enables longitudinal imaging of the same observation area, accurately quantifying multidimensional biomarkers and monitoring their changes over time, making it suitable for monitoring disease progression or treatment response. By identifying disease-specific multidimensional biomarkers, this application has successfully differentiated between benign and malignant diseases in clinical trials. This application can be seamlessly integrated into existing clinical ultrasound equipment workflows, enabling microvascular imaging, biomarker extraction, and analysis. The standardized operating procedures and automated analysis significantly lower the technical barrier to entry, assisting scientists and physicians in disease diagnosis and possessing direct potential for clinical application.

This application relates to the field of hematologic malignancies, autoimmune, inflammatory and fibrotic diseases, HIV as well as conditioning therapies for hematopoietic stem cell transplant (HSC-T), specifically to a chimeric antigen receptor that specifically binds CD45 and its use for treatment, such as to treat a malignancy, non-malignant or infectious diseases of the hematopoietic system in a subject.

An orally active, brain penetrant first-in-class small molecule midkine inhibitor for use in the treatment of triple-negative breast cancer, brain tumors (including glioblastoma, medulloblastoma, and NF1-mutant optic pathway gliomas), ovarian and endometrial cancers, lung cancer, as well as gynecologic non-malignant conditions such as endometriosis, uterine fibroids, and preterm birth, in which tumor cells and / or pathological cells exhibit heightened midkine signaling and express multiple midkine receptors.

Disclosed herein are poly-inflammatory kinase (PINK) inhibitors, compositions containing PINK inhibitors. Methods for treating malignant diseases and autoimmune disorders using the PINK inhibitors are also disclosed.

The present invention relates to specific binding molecules that bind the HLA-A*02 restricted peptide GLSPTVWLSV (SEQ ID NO: 1) derived from HBV envelope protein. The specific binding molecules may comprise alpha and / or beta TCR variable domains and may comprise non-natural mutations within the alpha and / or beta variable domains relative to a native TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of infectious or malignant disease.

The invention provides methods, compositions, and combinations for treating cancer or a non-malignant disease or condition in which αv and / or α5 (e.g., α5β1 ) integrin is expressed or implicated in pathogenesis or progression. The methods include administration of a bispecific antibody that specifically binds αv integrin and α5 (e.g., α5β1 ) integrin and a Src inhibitor to provide treatment for the cancer or non-malignant disease or condition.

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (9), formula (10), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

This invention discloses a comprehensive decision support method and system for potential oral malignant diseases, comprising: constructing a pre-diagnosis risk prediction agent that integrates patient behavioral risk factors, genetic susceptibility markers, and multispectral initial screening images; generating a malignancy probability trajectory and triggering tiered screening through a time-series prediction model; establishing an in-diagnosis precision assessment agent that performs differential homeomorphic registration of autofluorescence and narrowband imaging images to generate fused data, and constructing an interpretable reasoning network to locate critical areas of malignancy in conjunction with pathological grading; constructing a post-diagnosis dynamic monitoring agent that establishes a digital twin model based on lesion baseline data, extracts mucosal texture and vascular morphological evolution features from each follow-up visit to generate malignancy trend curves and individualized intervention strategies; and constructing a multi-agent co-evolutionary framework that uses desensitized full-cycle data to perform federated closed-loop iterative optimization of the parameters of each agent. This aims to improve the early identification accuracy of precancerous lesion malignancy risk and optimize clinical intervention pathways.

The invention discloses an oral cavity potential malignant disease canceration risk prediction system, electronic equipment and a medium, and the system comprises a molecular marker extraction module which is used for carrying out feature dimension reduction on a cell molecule level detection result of the inner surface of an oral cavity to obtain a first feature; the image processing module is used for extracting canceration features by using a pre-trained second model based on a neural network, and processing the canceration features to obtain second features; the text feature screening module is used for carrying out feature screening through feature weight analysis based on the text information of the patient to obtain a third feature; and the cancerization risk prediction module is used for identifying a patient with oral cancerization risk by using a constructed fourth model by taking the first feature, the second feature, the third feature and the combination thereof as input. According to the technical scheme, pertinence is high, high-risk and low-risk groups of OPMDs patient canceration are divided in combination with multi-modal data, the model performance is improved, meanwhile, use is easy and convenient, and a basis can be provided for making a diagnosis and treatment plan.